Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III

European Heart Journal

Volumn 20, Issue 2, 1999, Pages 128-135

  Hasdai, D ^a   Holmes Jr , D R ^a   Topol, E J ^b   Berger, P B ^a   Criger, D A ^c   Hochman, J S ^d   Bates, E R ^e   Vahanian, A ^f   Armstrong, P W ^g   Wilcox, R ^h   Ohman, E M ^c   Califf, R M ^c  

^a MAYO CLINIC   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f HÔPITAL TENON   (France)

^g UNIVERSITY OF ALBERTA   (Canada)

^h QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Alteplase; Cardiogenic shock; Randomized clinical trial; Reteplase; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BOLUS INJECTION; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; CHI-SQUARE DISTRIBUTION; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; SHOCK, CARDIOGENIC; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0032911136     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1282     Document Type: Article

References (40)

1. Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med 1994; 330: 1724-31.
2. Goldberg RJ, Gore JM, Alpert JS et al. Cardiogenic shock after acute myocardial infarction: Incidence and mortality from a community wide perspective 1975-1988. N Engl J Med 1991; 325: 1117-22.
3. Holmes Jr DR, Bates ER, Kleiman NS et al. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. J Am Coll Cardiol 1995; 26: 668-74.
4. Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991; 18: 1077-84.
5. Bengtson JR, Kaplan AJ, Pieper KS et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol 1992; 20: 1482-9.
6. Himbert D, Juliard JM, Steg G, Karrillon GJ, Aumont MC, Gourgon R. Limits of reperfusion therapy for immediate cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 1994; 74: 492-4.
7. Scheidt S, Wilner G, Mueller H et al. Intra-aortic balloon counterpulsation in cardiogenic shock: Reports of a cooperative clinical trial. N Engl J Med 1973; 288: 979-84.
8. Beyersdorf F, Acar C, Buckberg GD et al. Studies on prolonged acute regional ischemia: V. Metabolic support of remote myocardium during left ventricular power failure. J Thorac Cardiovasc Surg 1989; 98: 567-79.
9. Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O'Neill WW. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988; 78: 1345-51.
10. Hochman JS, Boland J, Sleeper LA et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Circulation 1995; 91: 873-81.
11. Eltchaninoff H, Simpfendorfer C, Franco I, Raymond RE, Casale PN, Whitlow PL. Early and 1-year survival rates in acute myocardial infarction complicated by cardiogenic shock: A retrospective study comparing coronary angioplasty with medical treatment. Am Heart J 1995; 130: 459-64.
12. Webb JG, Carere RG, Hilton JD et al. Usefulness of coronary stenting for cardiogenic shock. Am J Cardiol 1997; 79: 81-4.
13. Holmes Jr DR, Califf RM, Van de Werf F et al. Differences in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: Results from the GUSTO trial. Lancet 1997; 349: 75-8.
14. Berger PB, Holmes Jr DR, Stebbins AL, Bates ER, Califf RM, Topol EJ. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Trial: An observational study. Circulation 1997; 96: 122-7.
15. Lange RA, Hillis LD. Immediate angioplasty for acute myocardial infarction. N Engl J Med 1993; 328: 726-8.
16. Smalling RW. Molecular biology of plasminogen activators: What are the clinical implications of drug design? Am J Cardiol 1996; 78: 2-7.
17. Noble S, McTavish D. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs 1996; 52: 589-605.
18. Bode C, Smalling RW, Berg G et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation 1996; 94: 891-8.
19. Smalling RW, Bode C, Kalbfleisch J et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. Circulation 1995; 91: 2725-32.
20. International Joint Efficacy of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995; 346: 329-36.
21. Bode C, Nordt TK, Peter K, Smalling RW, Runge MS, Kubler W. Patency trials with reteplase (r-PA): What do they tell us? Am J Cardiol 1996; 78: 16-9.
22. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-23.
23. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
24. Col NF, Gurwitz JH, Alpert JS, Goldberg RJ. Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy. Am J Cardiol 1994; 73: 149-57.
25. Domanski MJ, Topool EJ. Cardiogenic shock: Current understandings and future research directions. Am J Cardiol 1994; 74: 724-6.
26. Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico. Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction. Lancet 1986; 1: 397-401.
27. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
28. The GUSTO IIb Investigators. A comparison of recombinant hirudin versus heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
29. The GUSTO Angiographie Investigators. The effects of tissue plasmonogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
30. Prewitt RM, Gu S, Garber PJ, Ducas J. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992; 20: 1626-33.
31. Prewitt RM, Gu S, Schick U, Ducas J. Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. J Am Coll Cardiol 1994; 23: 794-8.
32. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-5.
33. Stauffer JC, Urban P, Bleed D et al. Results of the 'Swiss' Multicenter Evaluation of Early Angioplasty for Shock Following Myocardial Infarction. Circulation 1997; 96: I-206.
34. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1: 545-9.
35. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 1: 525-30.
36. The GUSTO-IIb Angioplasty Substudy Investigators. An international randomized trial of 1138 patients comparing primary coronary angioplasty versus tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1621-8.
37. Purvis JA, McNeill AJ, Siddiqui RA et al. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion of the treatment of acute myocardial infarction. J Am Coll Cardiol 1994; 23: 6-10.
38. The Continuous Infusion Versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997; 337: 1124-30.
39. Yusuf S, Wittes J, Probsfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93-8.
40. Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase, and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992; 19: 433-40.